Satellos Bioscience (MSLE) Depreciation & Amortization (CF) (2025 - 2026)
Satellos Bioscience's (MSLE) quarterly Depreciation & Amortization (CF) came in at $1000.0 in Q1 2026, little changed year-on-year from $1000.0 in Q1 2025, and little changed on a QoQ basis from $1000.0 in Q1 2025.
Satellos Bioscience (MSLE) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has 2 years of Depreciation & Amortization (CF) data on file, last reported at $1000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0 in Q1 2026; TTM through Mar 2026 was $2000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $4000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $1000.0, roughly flat from $1000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for MSLE reached as high as $1000.0 in Q1 2025 and fell as low as $1000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Satellos Bioscience | 148.71 Mn | 148.71 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |